MetLife delivers strong Q1 2026 results with adjusted EPS up 23% to $2.42 and ROE at 17%, highlighting robust core performance. I find MET's fixed-income preferreds, especially Series F, compelling with yields near 6.5% and payout ratios under 4%, offering rare quality and safety. Common shares trade at a fair 8.5x forward P/E with limited near-term upside; total equity returns approximate 8% annually via buybacks and dividends.